China in the Global Healthcare Ecosystem

Download Report Introduction

Key takeaways

Covid-19 has not thwarted private, venture-backed healthcare companies from raising money and closing active deals.


VC-backed companies in China raised $6.7B (19% of global investment) in 2020

Biopharma leads other sectors with $3.4B invested, followed by dx/tools with $1.8B


Macroeconomic forces have not inhibited cross-border activity

In 2020, there has been an uptick in China-based investors participating in US and European deals


VC-backed companies have raised $4B+ on China’s public exchanges

This year, China has seen 18 companies IPO with a $1B+ market cap, led by the biopharma sector.